Nasdaq:US$16.90 (-0.82) | HKEX:HK$27.20 (-0.95) | AIM:£2.52 (-0.11)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases | 8 Apr 2024

HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior antitumor activity to daratumumab in preclinical B-cell malignancies models